Antiphospholipid antibodies (aPL) are both diagnostic markers for, and pathogenic drivers
of, antiphospholipid syndrome (APS). Although the presence of aPL is a necessary pre …

Summary β 2‐Glycoprotein I (β 2‐GPI) is a protein that circulates in blood at high
concentrations. The function of β 2‐GPI has long been an enigma. More than 20 years ago …

The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or
pregnancy morbidity in combination with the persistent presence of circulating …

In antiphospholipid syndrome (APS), antiphospholipid antibodies (aPL) binding to β2
glycoprotein I (β2GPI) induce endothelial cell–leukocyte adhesion and thrombus formation …

Current classification criteria for definite APS recommend the use of one or more of three
positive standardized laboratory assays, including anticardiolipin antibodies (aCL), lupus …

Obstetric complications are the hallmark of antiphospholipid syndrome. Recurrent
miscarriage, early delivery, oligohydramnios, prematurity, intrauterine growth restriction, fetal …

Tripodi A, de Groot PG, Pengo V (IRCCS Cà Granda Ospedale Maggiore Policlinico
Foundation and Università degli Studi di Milano, Milan, Italy; Utrecht University Medical …

Sepsis is a systemic host response to invasive infection by bacteria. Despite treatment with
antibiotics, current mortality rates are in the range of 20%-25%, which makes sepsis the …

The objectives of the 'Task Force on Catastrophic Antiphospholipid Syndrome (APS) and
Non-criteria APS Manifestations' were to assess the clinical utility of the international …

Background Anti-β2-glycoprotein-I (anti-β2GPI) were demonstrated to be pathogenic in the
antiphospholipid syndrome (APS). However, they can be detected in patients with no …